Collegium Pharmaceutical (COLL) Q3 Earnings and Revenues Lag Estimates
Portfolio Pulse from
Collegium Pharmaceutical (COLL) reported Q3 earnings of $1.61 per share, missing the Zacks Consensus Estimate of $1.66. This is an increase from $1.34 per share a year ago.
November 08, 2024 | 12:00 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Collegium Pharmaceutical's Q3 earnings of $1.61 per share fell short of the expected $1.66, though they improved from $1.34 a year ago.
The earnings miss is likely to negatively impact COLL's stock price in the short term as it did not meet analyst expectations, despite showing year-over-year growth.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100